Current management of CMV infection in cancer patients (solid tumors). Epidemiology and therapeutic strategies.

Autor:	García-Bustos V, Salavert M; Miguel Salavert Lletí. Unidad de Enfermedades Infecciosas. Hospital Universitario y Politécnico La Fe, Valencia. Av. Fernando Abril Martorell, nº 106. Valencia 46016. Spain. salavert_mig@gva.es., Blanes R, Cabañero D, Blanes M
Jazyk:	angličtina
Zdroj:	Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia [Rev Esp Quimioter] 2022 Oct; Vol. 35 Suppl 3, pp. 74-79. Date of Electronic Publication: 2022 Oct 24.
DOI:	10.37201/req/s03.16.2022
Abstrakt:	Little evidence is available regarding the incidence of CMV disease in patients with solid cancers. Latest data show that approximately 50 % of these patients with CMV PCR positivity developed clinically relevant CMV-viremia, and would require specific therapy. In the clinical arena, CMV reactivation is an important differential diagnosis in the infectological work up of these patients, but guidelines of management on this subject are not yet available. CMV reactivation should be considered during differential diagnosis for patients with a severe decline in lymphocyte counts when receiving chemoradiotherapy or immunochemotherapy with lymphocyte-depleting or blocking agents. Monitoring of CMV reactivation followed by the implementation of preemptive strategies or the establishment of early antiviral treatment improves the prognosis and reduces the morbidity and mortality of these patients. (©The Author 2022. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu